Navigation Links
Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C

ation Thursday, April 12.

PEGINTRON is approved in the United States for use alone or with ribavirin (800 mg/day) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.

Important Safety Information Regarding U.S. Labeling for PEGINTRON and REBETOL

Alpha interferons, including PEGINTRON, may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening signs or symptoms of these conditions should be withdrawn from therapy. In many but not all cases these disorders resolve after stopping PEGINTRON therapy.

Ribavirin causes hemolytic anemia. Anemia associated with REBETOL therapy may exacerbate cardiac disease that has led to fatal and nonfatal myocardial infarctions. Patients with a history of significant or unstable cardiac disease should not be treated with REBETOL. It is advised that complete blood counts (CBC) be obtained at baseline and at weeks 2 and 4 of therapy or more frequently if clinically indicated.

REBETOL and combination REBETOL/PEGINTRON therapy must not be used by women, or male partners of women, who are or may become pregnant during therapy and during the 6 months after stopping therapy. REBETOL and combination REBETOL/PEGINTRON therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Women of childbearing potential and men must use effective contraception (at least two reliable forms) during treatment and during the 6- month post-treatment follow-up period. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occur
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
7. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Major Manufacturer of Unapproved and Adulterated Drugs
10. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
(Date:7/30/2015)... July 30, 2015 Vermillion, Inc. ... gynecologic disease, announced today it will report ... the market close on Thursday, August 13, ... and webcast at 4:30pm Eastern.Conference Call and ... 4:30pm Eastern/1:30pm Pacific  Domestic: , ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... $5 Million Payment from Roche- , , ... (Nasdaq: MEMY ) today announced that it has ... R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive ... 212 patients in the Phase 2 trial, triggering a $5.0 ...
... MALVERN, Pa., Nov. 18 Arlington Medical Resources (AMR), ... diagnostic,imaging industries, finds that over $10 million of CSL ... quarter of 2008. Privigen is the newest,brand of intravenous ... of 2008. IVIG is a product created from the ...
Cached Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2
(Date:7/30/2015)... ... 2015 , ... Mullin/Ashley Associates, Inc. , an integrated ... the Service Industry Advertising Awards 12th annual national competition. , The awards ... University of Maryland Shore Regional Health. , A Gold Award was won by ...
(Date:7/30/2015)... ... 2015 , ... Google recently announced that it will be disclosing any incidents ... a June 8, 2015 article published by Nasdaq , the powerful tech company ... its computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may ...
(Date:7/30/2015)... ... July 30, 2015 , ... " ... which takes a look at small, medium, and large businesses making an impact ... conducted the business review and shared with viewers how DevExpress has provided software ...
(Date:7/30/2015)... ... 2015 , ... 24/7 Care At Home, a high-quality provider of comprehensive home ... the Centers for Medicare and Medicaid (CMS) have awarded its agency the highest star ... At Home’s agency is one of three top Orange County agencies to earn the ...
(Date:7/30/2015)... ... July 30, 2015 , ... The need for accessibility is never greater ... comfort to patients as well as visiting friends and family during these critical moments, ... , The stations - powered by ChargeItSpot , a Philadelphia-based startup that recently ...
Breaking Medicine News(10 mins):Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 2Health News:Mullin/Ashley Associates Takes Home Wins for Three Clients in the Service Industry Advertising Awards Annual Competition 3Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2
... A toxic pollutant spread by oil spills, forest fires ... and may represent a second way in which smoking ... the annual meeting of the Orthopaedic Research Society in ... University of Rochester Medical Center identified one ingredient in ...
... Whitemark Homes, Inc.,(OTC Bulletin Board: WTMK), ... letter of,intent to acquire Metiscan Holdings, Inc. ... owned subsidiary Metiscan Technologies, Inc.,headquartered in Dallas, ... products and services that streamline the management ...
... SpectraScience, Inc. (OTC,Bulletin Board: SCIE), a San Diego ... placed its LUMA Cervical Imaging System to detect,pre-cancers ... the,direction of Dr. Stephen Poliakoff., The LUMA ... detection of high-grade precancerous cervical abnormalities that have,the ...
... Vapotherm, the,global leader in High Flow Oxygen ... Robert Storey earned Maryland,s 2008 International,Business Leadership Award ... one of seven winners selected by the WTCI ... international,business. The award will be presented to Storey ...
... a result of mutations in a given cell that ... the University of Helsinki, Finland, has demonstrated that in ... development are mutations in the smooth muscle cells, previously ... of interactions between tissue types, and open up possibilities ...
... partner, DNA Research, officially launches Suracell ... expected to open soon, SOUTH ORANGE, N.J., ... leading provider of genetically directed,personalized age management programs, ... of worldwide partnerships to bring its cutting edge ...
Cached Medicine News:Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 2Health News:Toxins in cigarette smoke prevent stem cells from becoming cartilage 3Health News:Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc. 2Health News:South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device 2Health News:South Florida Gynecologic Oncologists Begin Using LUMA(R) Cervical Pre-Cancer Imaging Device 3Health News:Anti-Aging/Genetic Health Leader Suracell, Inc. Expands Internationally 2
Inquire...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With polished ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
Medicine Products: